PolyU showcases innovative research in AI and medicine-engineering integration at BIO International Convention 2025
PolyU participated in the BIO International Convention 2025 (BIO 2025) held in Boston from 16 to 19 June 2025. Showcasing its ground-breaking innovations and translational research across the fields of artificial intelligence (AI), medicine and engineering for global industry leaders, the University highlighted its interdisciplinary excellence and leading position in medical and health research.
The world’s largest biotechnology convention, BIO 2025 brought together over 20,000 industry leaders and professionals from about 70 countries and regions. It embraced all key aspects of the biotechnology ecosystem, spanning from research and development, clinical trials and manufacturing, to investment, business development and commercialisation.
Ten cutting-edge PolyU innovations in drug discovery, medical devices and diagnostics, biomedical engineering, rehabilitation technologies, optometry and food science were showcased at the Convention. Apart from presentations, the research teams also engaged in business forums and thematic discussions during the event to cultivate meaningful connections, forge strategic partnerships and explore new avenues for collaboration with global industry leaders.
PAIR scholars-led innovations exhibited at BIO 2025 include:
“PocNova™: Ultra-Fast Nucleic Acid Testing System”, led by Prof. Thomas LEE Ming-hung, Member of Research Institute for Sports Science and Technology (RISports) and Associate Professor of Department of Biomedical Engineering
“Hybrid Robotic IoT for Telerehabilitation after Stroke”, led by Prof. HU Xiaoling, Member of Research Institute for Smart Ageing (RISA) and RISports, and Associate Professor of the Department of Biomedical Engineering
“HAND-HEART: An AI-Based Hand Hygiene Augmented Reality Tool”, led by Prof. YANG Lin, Management Committee Member of Research Centre of Textiles for Future Fashion (RCTFF), Member of Research Centre for SHARP Vision (RCSV) and Associate Professor of the School of Nursing
“First-in-Class Antibiotic Therapeutics”, led by Prof. MA Cong, Member of Research Centre for Chinese Medicine Innovation (RCMI) and Associate Professor of Department of Applied Biology and Chemical Technology
“Novel Nutraceuticals for Neurodegenerative Diseases”, led by Prof. Simon LEE Ming-yuen, Management Committee Member of RCMI, Member of Research Institute for Future Food (RiFood) and RISA, and Chair Professor of Biomedical Sciences of the Department of Food Science and Nutrition
“AkkMore™: a Fungus- and Plant-based Supplement against Obesity and Prediabetes”, led by Dr Gail CHANG Jinhui, Member of RiFood and Research Assistant Professor of Department of Food Science and Nutrition
A special highlight of PolyU’s participation this year in the business presentation session was Prof. Ma Cong sharing his latest breakthrough in antibiotic therapeutics. Prof. Ma has led a research team to make a first-in-class antimicrobial drug discovery with a unique mechanism of action to tackle antimicrobial resistance. His innovative approach focuses on disrupting protein–protein interactions (PPIs) within the bacterial transcription complex — igniting hope for the development of new antimicrobial agents.
Building on its robust foundation in medical and health research, PolyU is dedicated to advancing interdisciplinary research at the convergence of medicine, AI, engineering, and data science, pioneering a new era of healthcare innovation, while also contributing to Hong Kong’s development into an international health and medical innovation hub.
Press release: https://polyu.me/4nb0HFA
Online coverage:
Mirage News - https://polyu.me/4kYPUg7